Ranked #5,404 of 8,699 institutional investors
Krensavage Asset Management, LLC
New York, NY
$256M
US stock portfolio at live prices · today −$1.7M (−0.67%)
Live prices, last trade 11:34 AM ET
- Value at quarter end (Q3 2026)
- $265M
- Change from Q2 2026
- +$2.2M (+0.82%)
- Positions
- 17 · 3 new, 1 sold out
- Filed
- Nov 17, 2026
Not counted in the ranking: none$55.7M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesUTHR 14.4%BMRN 12.5%ENTA 8.60%ABT 8.14%EXEL 7.73%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| UTHR United Therapeutics Corporation | 66,282 | $36.8M | 14.4% | Reduced −4% |
| BMRN BioMarin Pharmaceutical Inc. | 524,786 | $32.0M | 12.5% | Unchanged |
| ENTA Enanta Pharmaceuticals, Inc. | 2,866,138 | $22.0M | 8.60% | Unchanged |
| ABT Abbott Laboratories | 200,000 | $20.8M | 8.14% | Unchanged |
| EXEL Exelixis, Inc. | 299,393 | $19.8M | 7.73% | Reduced −19% |
| RARE Ultragenyx Pharmaceutical Inc. | 1,140,867 | $19.0M | 7.44% | Added +192% |
| SNY Sanofi | 333,946 | $15.6M | 6.08% | Added +3% |
| EMBC Embecta Corp. | 1,135,340 | $7.1M | 2.78% | Unchanged |
| ARDX Ardelyx, Inc. | 1,815,492 | $5.4M | 2.13% | Added +240% |
| BIIB Biogen Inc. | 20,000 | $5.0M | 1.95% | Unchanged |
| BNTX BioNTech SE | 59,523 | $4.8M | 1.89% | Unchanged |
| GSK GSK plc | 96,729 | $4.7M | 1.83% | Unchanged |
| VNDA Vanda Pharmaceuticals Inc. | 1,180,388 | $4.2M | 1.65% | Unchanged |
| ANIP ANI Pharmaceuticals, Inc. | 13,000 | $892K | 0.35% | New |
| ZTS Zoetis Inc. | 10,000 | $812K | 0.32% | New |
| ACAD Acadia Pharmaceuticals Inc. | 40,000 | $702K | 0.27% | New |
| EOLS Evolus, Inc. | 57,985 | $403K | 0.16% | Reduced −63% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | 6,000 | $5.6M |